Figure 1.

Disposition of patients through Week60 of the DISCOVER-1 rial. CRP, C reactive protein, TB, tuberculosis, TNFi, tumour necrosis factor inhibitor, Q4/8W, every 4/8 weeks. *One patient was accidentally randomly assigned before completion of the screening assessments. Subsequently, this patient did not pass screening and was later re-screened and randomly assigned using a new patient number. **One patient randomised to guselkumab 100 mg Q8W was not treated.